Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1584)	12/20/2006 5:48:21 PM
From: A.J. Mullen	Respond to of 2240

Yes, I held my nose when buying Medx. It seemed like a gift to the wife. She has done well with it though, given that she's a historian. Ashley

To: rkrw who wrote (1584)	12/20/2006 7:05:18 PM
From: LJM	Respond to of 2240

For some reason, I thought they did get royalties as well on product licenses. Apparently not, 16 product licenses require no further payment to Medarex. Talk about a sweetheart deal. Does anyone know what happens if GENMAB gets bought out by a pharma? Would access to UltiMAb be transferable? I admit owning a bunch of MEDX and had mistakenly thought GENMAB success would pass more of the wealth downstream to MEDX. From the GENMAB website: Genmab has a unique alliance with Medarex that gives us access to the UltiMAb® system for creating the full range of human antibody isotypes. Under this agreement, Genmab has the right to obtain licenses for an unlimited number of antibodies and owns the worldwide development and commercialization rights to these products. Genmab’s principal obligation under this agreement is to make royalty payments in connection with any such product licenses. Genmab received these rights in exchange for stock in the company, and we also received 16 fully paid up product licenses, which require no further payments to Medarex.